CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4⁺ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Dunn JP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm100
   PubMed Web of Science ®Google Scholar
• Vesely M, Kershaw M, Schreiber R, Smyth M. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324
   PubMed Web of Science ®Google Scholar
• Germain RN, Margulies DH. The biochemistry and cellular biology of antigen processing and presentation. Annu Rev Immunol 1993; 11:403-50; PMID:8476568.; http://dx.doi.org/10.1146/annurev.iy.11.040193.02155
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells: versatile controllers of the immune system. Nature Med 2007; 13:1155-9; PMID:17917664; http://dx.doi.org/10.038/nm643
   PubMedGoogle Scholar
• Pardoll DM, Topalian SL. The role of CD4+ T cell responses in anti-tumor immunity. Curr Opin Immunol 1998; 10:588-94; PMID:9794842; http://dx.doi.org/10.1016/S0952-7915(98)80228-8
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll DM, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998; 188:2357-68; PMID:9858522; http://dx.doi.org/10.1084/jem.188.12.2357
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12:337-65; PMID:8011285; http://dx.doi.org/10.1146/annurev.iy.12.040194.02005
   PubMed Web of Science ®Google Scholar
• Meazza R, Comes A, Orengo AM, Ferrini S, and Accolla RS. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol 2003; 33:1183-92; PMID:12731043; http://dx.doi.org/10.58/078-0432.CCR-06-165
   PubMedGoogle Scholar
• Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res 2006; 12:3435-43; PMID:16740768; http://dx.doi.org/10.1158/078-0432.CCR-06-165
   PubMed Web of Science ®Google Scholar
• Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int Immunol 2009; 21:655-65; PMID:19395374; http://dx.doi.org/10.1093/intimm/dxp034
   PubMed Web of Science ®Google Scholar
• Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy. Int J Cancer 2010; 127:1614-24; PMID:20091859; http://dx.doi.org/10.002/ijc.25183
   PubMedGoogle Scholar
• Accolla RS, Tosi G. Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy. J Neuroimmune Pharmacol 2013; 8:28-36; PMID:23224729; http://dx.doi.org/10.1007/s11481-012-9423-7
   PubMed Web of Science ®Google Scholar
• Accolla RS, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G. Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state. Frontiers Oncol 2014; 4:32; PMID:23986750; http://dx.doi.org/10.3389/fonc.2014.00032
   PubMedGoogle Scholar
• Mathis DJ, Benoist C, Williams VE, Kanter M, McDevitt HO. Several mechanisms can account for defective Ea gene expression in different mouse haplotypes. Proc Natl Acad Sci USA 1983; 80:273-7; PMID:6296871; http://dx.doi.org/10.1073/pnas.80.1.273
   PubMed Web of Science ®Google Scholar
• Hochweller K, Striegler J, Hammerling GJ, Garbi N. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol 2008; 38:2776-83; PMID:18825750; http://dx.doi.org/10.1002/eji.200838659
   PubMed Web of Science ®Google Scholar
• Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174:83-93; PMID:8083541; http://dx.doi.org/10.1016/0022-1759(94)90012-4
   PubMed Web of Science ®Google Scholar
• Probst HC, Tschannen K, Odermatt B, Schwendener R, Zinkernagel RM, Van Den Broek M. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clin Exp Immunol 2005; 141:398-404; PMID:16045728; http://dx.doi.org/10.1111/j.365-2249.005.02868.x
   PubMed Web of Science ®Google Scholar
• Bernhard CA, Ried C, Kochanek S, Brocker T. CD169+ macrophages are sufficient for priming of CTLs with specificities left out by crosspriming dendritic cells. Proc Natl Acad Sci USA 2015; 112:5461-6; PMID:25922518; http://dx.doi.org/10.1073/pnas.1423356112
   PubMed Web of Science ®Google Scholar
• Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur J Immunol 1997; 27:2626-33; PMID:9368619; http://dx.doi.org/10.1002/eji.1830271023
   PubMed Web of Science ®Google Scholar
• Sartoris S, Valle MT, De Lerma Barbaro A, Tosi G, Cestari T, D'Agostino A, Megiovanni AM, Manca F, Accolla RS. HLA class II expression in uninducible hepatocarcinoma cells after trasfection of the AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. J Immunol 1998; 161:814-20; PMID:9670958
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.16/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48; PMID:15771580; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611
   PubMed Web of Science ®Google Scholar
• Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nature Rev Immunol 2006; 6:205-17; PMID:16498451; http://dx.doi.org/10.1038/nri786
   PubMed Web of Science ®Google Scholar
• Dieu-Nosjean MC, Goc J, Giraldo NA, Sautes-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014; 35:571-80; PMID:25443495; http://dx.doi.org/10.1016/j.it.2014.09.006
   PubMed Web of Science ®Google Scholar
• Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or Bare Lymphocyte Syndrome). Cell 1993; 75:135-46; PMID:8402893; http://dx.doi.org/10.1016/S0092-8674(05)80090-X
   PubMed Web of Science ®Google Scholar
• van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of and propamidine. J Immunol Methods 1996; 193:93-9; PMID:8690935; http://dx.doi.org/10.1016/0022-1759(96)00056-7
   PubMed Web of Science ®Google Scholar